GE Healthcare and Optellum Join Forces to Advance Lung Cancer Diagnosis with Artificial Intelligence
November 26 2021 - 8:00AM
Business Wire
GE Healthcare and Optellum today announced that they have signed
a letter of intent to collaborate to advance precision diagnosis
and treatment of lung cancer. GE Healthcare is a global leader in
medical imaging solutions. Optellum is the leader in AI decision
support for the early diagnosis and optimal treatment of lung
cancer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211126005396/en/
A clinician and research scientist
evaluate lung nodules using Optellum software (Photo: Business
Wire)
Together, the companies are seeking to address one of the
largest challenges in the diagnosis of lung cancer, helping
providers to determine the malignancy of a lung nodule: a
suspicious lesion that may be benign or cancerous. The majority of
incidentally detected pulmonary nodules present an indeterminate
cancer risk, and are incredibly challenging for clinicians to
diagnose and manage, leading to delayed treatment for cancer
patients and invasive procedures on healthy people.
Optellum’s Virtual Nodule Clinic identifies and scores the
probability of malignancy in a lung nodule, which is key to
determining whether biopsy is necessary, and accelerating
diagnosis. It is the only FDA-cleared AI-assisted diagnosis
software for early-stage lung cancer1, and has been shown to
improve the sensitivity and specificity of malignancy assessments
of indeterminate nodules 2 — enabling pulmonologists and
radiologists to make optimal clinical decisions3.
The clinician’s AI-assisted diagnosis of malignancy may enable
patients whose nodules are not malignant to avoid unnecessary and
aggressive procedures such as biopsy and surgical resection, while
expediting the diagnostic process, and enabling the right treatment
to start earlier. This has the potential to provide patients with
personalized diagnosis and treatment plans, enabling lung cancer
patients to be treated at the earliest possible stage when survival
rates are the highest.
GE plans to collaborate with Optellum’s sales team on the
distribution of the Virtual Nodule Clinic and work with Optellum to
integrate the platform with AI solutions powered by GE Healthcare’s
Edison platform. In addition the companies intend to bring results
from Optellum’s Lung Cancer Prediction AI into the existing
workflow of various GE Healthcare technological pathways, including
CT and PACS.
“The precise diagnosis of lung cancer can greatly improve
patient prognosis,” said Ben Newton, General Manager, Oncology
Solutions, at GE Healthcare. “The integration of imaging and
medical device data from the Edison Platform with AI-enabled
solutions like the one offered by the Optellum Virtual Nodule
Clinic has the potential to streamline clinician workflows and
advance our goal of making precision healthcare, taking the right
action at the right time for every patient, at scale, as widely
accessible as possible.”
“This collaboration is a major step forward for Optellum and the
field of thoracic oncology at large,” commented Václav Potěšil,
PhD, Founder and Chief Business Officer of Optellum. “GE’s vast
clinical network can accelerate deployment of Optellum’s platform
and could enable a revolutionary redefinition of early lung cancer
treatment for clinicians and patients around the world.”
About GE Healthcare
GE Healthcare is the $17 billion* healthcare business of GE
(NYSE: GE). As a leading global medical technology, pharmaceutical
diagnostics and digital solutions innovator, GE Healthcare enables
clinicians to make faster, more informed decisions through
intelligent devices, data analytics, applications and services,
supported by its Edison intelligence platform. With over 100 years
of healthcare industry experience and around 47,000 employees
globally, the company operates at the center of an ecosystem
working toward precision health, digitizing healthcare, helping
drive productivity and improve outcomes for patients, providers,
health systems and researchers around the world.
*excludes Biopharma
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights
for the latest news, or visit our website www.gehealthcare.com for
more information.
About Optellum
Optellum is a commercial-stage lung health company providing
Artificial Intelligence decision support software that assists
physicians in early diagnosis and optimal treatment for their
patients. The company was founded so that every lung disease
patient is diagnosed and treated at the earliest possible stage,
when chances of cure are the highest. Optellum’s roadmap extends
beyond lung cancer diagnosis and treatment to other deadly diseases
of the lungs, including interstitial lung disease (ILD) and chronic
obstructive pulmonary disease (COPD). Optellum has headquarters at
the Oxford Centre for Innovation in Oxford, United Kingdom and a
U.S. office at the Texas Medical Center in Houston, TX.
For more information, visit optellum.com, or follow us LinkedIn
and Twitter.
1EIT Health
https://eithealth.eu/news-article/eit-health-supported-optellum-marks-ai-world-first/
2 Massion PP, Antic S, Ather S, et al. Assessing the Accuracy of a
Deep Learning Method to Risk Stratify Indeterminate Pulmonary
Nodules. Am J Respir Crit Care Med. 2020 Jul 15;202(2):241-249.
https://www.atsjournals.org/doi/full/10.1164/rccm.201903-0505OC
3Vachani A, Massion P, Munden R, Gleeson F, Bellinger C, Dotson T,
Freitag L, Imaging AI/”Radiomics” decision support improves
physicians’ stratification of indeterminate pulmonary nodules: A
Multiple-Reader Multiple-Case study presented to The ACS National
Lung Cancer Roundtable (NLCRT) 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211126005396/en/
Media Contacts: Hannah Huntly Hannah.Huntly@ge.com +44
7887 824201
Rhiannon Lassiter Rhiannon.Lassiter@optellum.com
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Mar 2024 to Apr 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Apr 2023 to Apr 2024